Portal de Periódicos da CAPES

Challenges in Obtaining Adequate Genetic Sample Sets in Clinical Trials: The Perspective of the Industry Pharmacogenomics Working Group

2011; Wiley; Volume: 89; Issue: 4 Linguagem: Inglês

10.1038/clpt.2010.305

1532-6535

Amelia Warner, Anahita Bhathena, Sandra Gilardi, D M Mohr, Diane U. Leong, Karina Bienfait, J Sarang, Sheena Duprey, M A Franc, Andrew C. Nelsen, Amir Snapir,

Pharmaceutical studies and practices

Collection of DNA samples from subjects participating in clinical trials is vital to understanding variability in drug response. The purpose of this study was to assess pharmacogenetic sample-collection practices in the industry and to gather information on issues affecting collection. A survey questionnaire was developed and distributed to 20 pharmaceutical companies; 15 provided responses. Assessments included rate of DNA sample collection, reasons for low collection rates, reasons for rejection by health authorities (HAs) and institutional review boards/ethics committees (IRBs/ECs), and country-specific hurdles to sample collection. The results indicated that, although DNA samples are frequently collected, sample-acquisition rates remain lower than expected. Overall, the companies' experience has been that restrictions on sample usage are not consistently applied by regulatory bodies. This may reflect changing opinions/interpretations of HAs/IRBs/ECs. Collection of DNA samples in industry trials is still a challenge. Harmonization of sample-collection practices may facilitate the process.